arrow
A

Alessandra Fabbri

istituto di ricerche farmacologiche mario negri irccs
H指数:26
被引数:3,243

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Oncocytic and spindle cell typical carcinoids of lung: different immunophenotype and biological behavior
2025-03-010
OAAI
CXCR4 Expression Increases in Platinum-Based Treated Non-Small Cell Lung Cancer and is Associated with a Worsening Trend in Progression Free Survival e A Clinical-Based Population Study Confirms Preclinical Models
2025-03-010
PRE
Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectives

标记无效的肺大细胞癌的两种转录组亚型的表征表明不同的起源和潜在的新治疗观点

2024-01-030
OAAI
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers

人 (NCT03447678),一线II期pembrolizumab试验,在阴性和低PD-L1晚期NSCLC中: 临床结果和与循环免疫生物标志物的关联

2022-12-015
OAAI
Lung carcinoid tumours: histology and Ki-67, the eternal rivalry
2022-10-2620
OAAI
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology
2022-01-0113
PRE
Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy
2020-07-302
OAAI
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial
2019-05-0130
PRE
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)

胸腺上皮肿瘤管理的最佳实践: 意大利胸腺恶性肿瘤协作组 (TYME) 的立场文件

2018-12-0144
OAAI
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma
2018-09-0115
PREAI
RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients
2018-08-0312
OAAI
RanBP9 protects cells from genotoxic stress and increased expression is predictive of worse response to platinum in NSCLC patients
2018-01-010
PRE